Navigation Links
ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
Date:8/22/2007

SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq: ZGEN) announced that the company will hold a conference call today to provide an update on the regulatory review of recombinant thrombin (rThrombin).

The ZymoGenetics conference call may be accessed on August 22 at 5:00 p.m. Eastern Time by dialing 877-407-0782 (International: 201-689-8567). Participants should dial in to the call approximately 10 minutes prior to the scheduled start time to register. The webcast can be accessed at http://www.zymogenetics.com (in the Investor Relations Events section). The conference call and live webcast will be archived for 30 days.

For replay, please visit http://www.zymogenetics.com or use the following information:

-- U.S. callers: 877-660-6853

-- International callers: 201-612-7415

Replay passcode account #: 286

Conference ID #: 253354

About ZymoGenetics

ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of proprietary product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit http://www.zymogenetics.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future actions or performance and may involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation and other risks detailed in the company's public filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.

Investor and Media Relations

Susan W. Specht, MBA

Associate Director, Corporate Communications

(206) 442-6592


'/>"/>
SOURCE ZymoGenetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Digital Healthcare Conference 2007: Mounting obstacles for health IT
2. Biomedical engineering conference invites manufacturers
3. Conference to address small town development
4. Wisconsin to host SBIR Conference
5. Gaming conference explores interactive media in learning
6. Digital Healthcare Conference starts on a realistic note
7. Digital Healthcare Conference marks Wisconsins Healthcare IT Week
8. Third coast of biotechnology makes strong showing at VC conference
9. Why companies dont get invited to the DEMO conference
10. Giuliani will keynote RedPrairie Corporations user conference
11. Wicab to present BrainPort at Boston conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... 27, 2017 , ... Arrowhead Publishers is pleased to announce ... to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, biotech, ... in the treatment of various types of pain. There are also extended networking ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... the 2017 Borlaug CAST Communication Award goes to Jayson Lusk, a consummate communicator ... forms of media to advocate for science, as he explains how innovation and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ... I clinical trials comes to Tampa, San Francisco and Boston in 2017. ... FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix ...
(Date:4/26/2017)... 26, 2017  Genisphere LLC, provider of the ... a collaborative and sponsored research agreement with the ... . The overall goal of the partnership is ... 3DNA designs and formulations after in vivo ... the vasculature as well as inflammatory responses, demonstrating ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):